Fifth Third Bancorp’s Ocular Therapeutix OCUL Stock Holding History

Fifth Third Bancorp’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-500	Closed	-$2.63K	–	2720
2023 Q1	$2.63K	Buy	+500	New	+$2.37K	﹤0.01%	2507

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Fifth Third Bancorp's OCUL Position: Q2 2023 in Review

Fifth Third Bancorp sold out of Ocular Therapeutix (OCUL) in Q2 2023, closing a stake of 500 shares — an estimated $2.63K sold.

Fifth Third Bancorp first reported a position in OCUL in Q1 2023 and held it in 1 quarter. The position peaked at $2.63K in Q1 2023. 135 funds tracked by Wall St. Rank hold OCUL as of Q2 2023.

Fifth Third Bancorp reported no remaining Ocular Therapeutix position as of Q2 2023 after selling out during the quarter.
Fifth Third Bancorp sold 500 Ocular Therapeutix shares in Q2 2023, an estimated $2.63K.
Fifth Third Bancorp first reported a position in Ocular Therapeutix in Q1 2023 and held it in 1 quarter.
Fifth Third Bancorp's Ocular Therapeutix position peaked at $2.63K in Q1 2023.
135 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2023.

Based on Fifth Third Bancorp's 13F filing for Q2 2023, filed 26 Jul 2023.